COMPARISON
Angiotensin II vs Lanreotide
5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Angiotensin II is authorised or registered in 3 and Lanreotide in 9 of the 10 registers read. Angiotensin II: highest phase Phase 4 (after approval). Lanreotide: highest phase Phase 4 (after approval). 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Angiotensin II | Lanreotide | |
|---|---|---|
| Registered trials differs | 364 clinicaltrials.gov · 2026-10-03 | 125 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: ANGIOTENSIN II openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Lanreotide Acetate openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Authorised ema · 2026-10-03 | Nothing on record ema read 2026-08-31 |
| EU authorised on differs | 2019-08-23 ema · 2026-10-03 | Not checked no record of "authorisedOn" for lanreotide |
| ATC code differs | C09 ema · 2026-10-03 | Not checked no record of "atcCode" for lanreotide |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Angiotensin II | placebo | Lanreotide | placebo |
|---|---|---|---|---|
| Hypertension | 5.5% | 5.7% | 8.8% | 5.6% |
| Multi-organ failure | 15.3% | 14.6% | - | - |
| Septic shock | 11.0% | 6.3% | - | - |
| Atrial fibrillation | 10.4% | 10.1% | - | - |
| Thrombocytopenia | 9.2% | 6.3% | - | - |
| Hypokalaemia | 8.0% | 6.3% | - | - |
| Hypotension | 8.0% | 4.4% | - | - |
| Anaemia | 6.7% | 5.7% | - | - |
| Delirium | 5.5% | 0.6% | - | - |
| Pleural effusion | 4.9% | 5.1% | - | - |
| Diarrhoea | - | - | 19.5% | 23.6% |
| Abdominal pain | - | - | 16.8% | 15.9% |
| Fatigue | - | - | 12.2% | 14.6% |
| Nausea | - | - | 11.0% | 12.0% |
| Vomiting | - | - | 10.8% | 7.8% |
| Headache | - | - | 10.7% | 9.4% |
| Arthralgia | - | - | 8.0% | 8.2% |
| Back pain | - | - | 8.0% | 10.3% |
| Decreased appetite | - | - | 8.0% | 8.6% |
Trial register Angiotensin II: 1 placebo-controlled trials; Lanreotide: 5. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Angiotensin II side effects · Lanreotide side effects
LEGAL STATUS
Approval in each country read
| Country | Angiotensin II | Lanreotide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Not on the register | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Not on the register | Authorised | Regulator Health Canada |
| Australia | Status unknown | Registered | TGA |
| Switzerland | Not on the register | Authorised | Regulator Swissmedic |
| Brazil | Not on the register | Registado | Regulator ANVISA |
| Serbia | Not on the register | Authorised | Regulator ALIMS |
| Singapore | Not on the register | Registered | Regulator HSA |
| Turkey | Not on the register | Ruhsatli | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.